Literature DB >> 8439960

Mutagenic processing of ethylation damage in mammalian cells: the use of methoxyamine to study apurinic/apyrimidinic site-induced mutagenesis.

P Fortini1, A Calcagnile, H Vrieling, A A van Zeeland, M Bignami, E Dogliotti.   

Abstract

The aldehyde reagent methoxyamine is able to interact with apurinic/apyrimidinic sites formed in vivo within cells and displays both an anti-cytotoxic and an antimutagenic activity on N-ethyl-N'-nitro-N-nitrosoguanidine-induced DNA damage in Chinese hamster ovary cells. To clarify the underlying mechanism we have examined the mutational spectra induced by N-ethyl-N'-nitro-N-nitrosoguanidine alone and in the presence of methoxyamine in the hypoxanthine-guanine phosphoribosyltransferase gene of Chinese hamster ovary cells. In both cases all mutations were base pair substitutions, and their distribution among various classes did not differ significantly. Almost 60% were transitions, predominantly GC to AT, and the remaining 40% were transversions, mainly at AT base pairs. The analysis of the proportion of the different types of mutations showed that in the presence of methoxyamine, GC to AT transitions decreased by a factor of 1.8, and AT to CG transversions were reduced by a factor of 13. These data indicate that in mammalian cells the fixation of ethylation damage into mutations occurs by both (a) direct mutagenesis likely driven by O6-ethylguanine adducts and to a minor extent by O4-ethylthymine and (b) apurinic/apyrimidinic site-mediated mutagenesis. These apurinic/apyrimidinic sites are formed during the processing of ethylation at critical sites and are likely to involve O6-ethylguanine and O2-ethylthymine adducts.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8439960

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide.

Authors:  Ana P Montaldi; Elza T Sakamoto-Hojo
Journal:  Clin Exp Med       Date:  2012-07-25       Impact factor: 3.984

2.  Photooxidation of d(TpG) by riboflavin and methylene blue. Isolation and characterization of thymidylyl-(3',5')-2-amino-5-[(2-deoxy-beta-D- erythro-pentofuranosyl)amino]-4H-imidazol-4-one and its primary decomposition product thymidylyl-(3',5')-2,2-diamino-4-[(2-deoxy-beta-D- erythro-pentofuranosyl)amino]-5(2H)-oxazolone.

Authors:  G W Buchko; J Cadet; B Morin; M Weinfeld
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

3.  Increased removal of 3-alkyladenine reduces the frequencies of hprt mutations induced by methyl- and ethylmethanesulfonate in Chinese hamster fibroblast cells.

Authors:  A Klungland; M Bjørås; E Hoff; E Seeberg
Journal:  Nucleic Acids Res       Date:  1994-05-11       Impact factor: 16.971

Review 4.  Defining a genotoxic profile with mouse embryonic stem cells.

Authors:  Tae Moon Kim; Vivienne I Rebel; Paul Hasty
Journal:  Exp Biol Med (Maywood)       Date:  2013-03

5.  Repair of abasic sites by mammalian cell extracts.

Authors:  G Frosina; P Fortini; O Rossi; F Carrozzino; A Abbondandolo; E Dogliotti
Journal:  Biochem J       Date:  1994-12-15       Impact factor: 3.857

6.  Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions.

Authors:  Yanlin Jiang; Chunlu Guo; Melissa L Fishel; Zheng-Yu Wang; Michael R Vasko; Mark R Kelley
Journal:  DNA Repair (Amst)       Date:  2009-09-01

7.  Specificity of the mutator caused by deletion of the yeast structural gene (APN1) for the major apurinic endonuclease.

Authors:  B A Kunz; E S Henson; H Roche; D Ramotar; T Nunoshiba; B Demple
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

Review 8.  New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors.

Authors:  Melissa S Bentle; Erik A Bey; Ying Dong; Kathryn E Reinicke; David A Boothman
Journal:  J Mol Histol       Date:  2006-07-26       Impact factor: 3.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.